Noninvasive, Blood-Based Biomarkers as Screening Tools for Hepatic Fibrosis in People With Type 2 Diabetes

Noninvasive, Blood-Based Biomarkers as Screening Tools for Hepatic Fibrosis in People With Type 2 Diabetes

Nonalcoholic fatty liver disease (NAFLD) is dramatically increasing in parallel with the pandemic of type 2 diabetes. Here, the authors aimed to assess the performance of the most commonly used noninvasive, blood-based biomarkers for liver fibrosis (FibroTest, NAFLD fibrosis score, BARD score, and F...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical diabetes 2022-01, Vol.40 (3), p.327-338
Hauptverfasser: Meritsi, Angeliki, Latsou, Dimitra, Manesis, Emanuel, Gatos, Ilias, Theotokas, Ioannis, Zoumpoulis, Pavlos, Rapti, Stamatia, Tsitsopoulos, Eustathios, Moshoyianni, Hariklia, Manolakopoulos, Spilios, Pektasides, Dimitrios, Thanopoulou, Anastasia
Format: Artikel
Sprache:eng
Schlagworte:
Biomarkers
Diabetes
Liver diseases
Medical screening
Pandemics
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 338
container_issue 3
container_start_page 327
container_title Clinical diabetes
container_volume 40
creator Meritsi, Angeliki
Latsou, Dimitra
Manesis, Emanuel
Gatos, Ilias
Theotokas, Ioannis
Zoumpoulis, Pavlos
Rapti, Stamatia
Tsitsopoulos, Eustathios
Moshoyianni, Hariklia
Manolakopoulos, Spilios
Pektasides, Dimitrios
Thanopoulou, Anastasia
description Nonalcoholic fatty liver disease (NAFLD) is dramatically increasing in parallel with the pandemic of type 2 diabetes. Here, the authors aimed to assess the performance of the most commonly used noninvasive, blood-based biomarkers for liver fibrosis (FibroTest, NAFLD fibrosis score, BARD score, and FIB-4 Index) in subjects with type 2 diabetes. Liver stiffness measurement was estimated by two-dimensional shear wave elastography. Finally, the authors assessed the diagnostic role of ActiTest and NashTest 2 in liver fibrosis in the examined population.
doi_str_mv 10.2337/cd21-0104
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9331611</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2704871839</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3184-fdc24528191f8419f5e2bb608898087e87ac0ec61a56554ba84f97ebdb312d3f3</originalsourceid><addsrcrecordid>eNpdkU1P3DAQhi3UCrbAoX-gssSFSg31-COxL5VYPkolVCp1UY-W40zA22yc2tmV-PdkBUWlpznMo1fvzEPIe2AnXIjqs284FAyY3CEzMFIV0ijxhsyYNlBow80eeZfzkjGmONe7ZE8oo4XkakaW32Mf-o3LYYOf6LyLsSnmLmND5yGuXPqNKVOX6U-fECfyji5i7DJtY6JXOLgxeHoZ6hRzyDT09AfGoUP6K4z3dPEwIOX0PLgaR8wH5G3ruoyHz3Of3F5eLM6uiuubr9_OTq8LL0DLom08l4prMNBqCaZVyOu6ZFobzXSFunKeoS_BqVIpWTstW1Nh3dQCeCNasU--POUO63qFjcd-TK6zQwrTPQ82umBfb_pwb-_ixhohoASYAo6fA1L8s8Y82lXIHrvO9RjX2fKKSV2BFmZCj_5Dl3Gd-uk8y0sDzChWbqmPT5Sf_pQTti9lgNmtQbs1aLcGJ_bDv-1fyL_KxCOBG5Xg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2691095069</pqid></control><display><type>article</type><title>Noninvasive, Blood-Based Biomarkers as Screening Tools for Hepatic Fibrosis in People With Type 2 Diabetes</title><source>PMC (PubMed Central)</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Meritsi, Angeliki ; Latsou, Dimitra ; Manesis, Emanuel ; Gatos, Ilias ; Theotokas, Ioannis ; Zoumpoulis, Pavlos ; Rapti, Stamatia ; Tsitsopoulos, Eustathios ; Moshoyianni, Hariklia ; Manolakopoulos, Spilios ; Pektasides, Dimitrios ; Thanopoulou, Anastasia</creator><creatorcontrib>Meritsi, Angeliki ; Latsou, Dimitra ; Manesis, Emanuel ; Gatos, Ilias ; Theotokas, Ioannis ; Zoumpoulis, Pavlos ; Rapti, Stamatia ; Tsitsopoulos, Eustathios ; Moshoyianni, Hariklia ; Manolakopoulos, Spilios ; Pektasides, Dimitrios ; Thanopoulou, Anastasia</creatorcontrib><description>Nonalcoholic fatty liver disease (NAFLD) is dramatically increasing in parallel with the pandemic of type 2 diabetes. Here, the authors aimed to assess the performance of the most commonly used noninvasive, blood-based biomarkers for liver fibrosis (FibroTest, NAFLD fibrosis score, BARD score, and FIB-4 Index) in subjects with type 2 diabetes. Liver stiffness measurement was estimated by two-dimensional shear wave elastography. Finally, the authors assessed the diagnostic role of ActiTest and NashTest 2 in liver fibrosis in the examined population.</description><identifier>ISSN: 0891-8929</identifier><identifier>EISSN: 1945-4953</identifier><identifier>DOI: 10.2337/cd21-0104</identifier><identifier>PMID: 35983425</identifier><language>eng</language><publisher>United States: American Diabetes Association</publisher><subject>Biomarkers ; Diabetes ; Liver diseases ; Medical screening ; Pandemics</subject><ispartof>Clinical diabetes, 2022-01, Vol.40 (3), p.327-338</ispartof><rights>2022 by the American Diabetes Association.</rights><rights>Copyright American Diabetes Association Summer 2022</rights><rights>2022 by the American Diabetes Association 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3184-fdc24528191f8419f5e2bb608898087e87ac0ec61a56554ba84f97ebdb312d3f3</citedby><cites>FETCH-LOGICAL-c3184-fdc24528191f8419f5e2bb608898087e87ac0ec61a56554ba84f97ebdb312d3f3</cites><orcidid>0000-0001-9361-9459</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331611/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9331611/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35983425$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Meritsi, Angeliki</creatorcontrib><creatorcontrib>Latsou, Dimitra</creatorcontrib><creatorcontrib>Manesis, Emanuel</creatorcontrib><creatorcontrib>Gatos, Ilias</creatorcontrib><creatorcontrib>Theotokas, Ioannis</creatorcontrib><creatorcontrib>Zoumpoulis, Pavlos</creatorcontrib><creatorcontrib>Rapti, Stamatia</creatorcontrib><creatorcontrib>Tsitsopoulos, Eustathios</creatorcontrib><creatorcontrib>Moshoyianni, Hariklia</creatorcontrib><creatorcontrib>Manolakopoulos, Spilios</creatorcontrib><creatorcontrib>Pektasides, Dimitrios</creatorcontrib><creatorcontrib>Thanopoulou, Anastasia</creatorcontrib><title>Noninvasive, Blood-Based Biomarkers as Screening Tools for Hepatic Fibrosis in People With Type 2 Diabetes</title><title>Clinical diabetes</title><addtitle>Clin Diabetes</addtitle><description>Nonalcoholic fatty liver disease (NAFLD) is dramatically increasing in parallel with the pandemic of type 2 diabetes. Here, the authors aimed to assess the performance of the most commonly used noninvasive, blood-based biomarkers for liver fibrosis (FibroTest, NAFLD fibrosis score, BARD score, and FIB-4 Index) in subjects with type 2 diabetes. Liver stiffness measurement was estimated by two-dimensional shear wave elastography. Finally, the authors assessed the diagnostic role of ActiTest and NashTest 2 in liver fibrosis in the examined population.</description><subject>Biomarkers</subject><subject>Diabetes</subject><subject>Liver diseases</subject><subject>Medical screening</subject><subject>Pandemics</subject><issn>0891-8929</issn><issn>1945-4953</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkU1P3DAQhi3UCrbAoX-gssSFSg31-COxL5VYPkolVCp1UY-W40zA22yc2tmV-PdkBUWlpznMo1fvzEPIe2AnXIjqs284FAyY3CEzMFIV0ijxhsyYNlBow80eeZfzkjGmONe7ZE8oo4XkakaW32Mf-o3LYYOf6LyLsSnmLmND5yGuXPqNKVOX6U-fECfyji5i7DJtY6JXOLgxeHoZ6hRzyDT09AfGoUP6K4z3dPEwIOX0PLgaR8wH5G3ruoyHz3Of3F5eLM6uiuubr9_OTq8LL0DLom08l4prMNBqCaZVyOu6ZFobzXSFunKeoS_BqVIpWTstW1Nh3dQCeCNasU--POUO63qFjcd-TK6zQwrTPQ82umBfb_pwb-_ixhohoASYAo6fA1L8s8Y82lXIHrvO9RjX2fKKSV2BFmZCj_5Dl3Gd-uk8y0sDzChWbqmPT5Sf_pQTti9lgNmtQbs1aLcGJ_bDv-1fyL_KxCOBG5Xg</recordid><startdate>20220101</startdate><enddate>20220101</enddate><creator>Meritsi, Angeliki</creator><creator>Latsou, Dimitra</creator><creator>Manesis, Emanuel</creator><creator>Gatos, Ilias</creator><creator>Theotokas, Ioannis</creator><creator>Zoumpoulis, Pavlos</creator><creator>Rapti, Stamatia</creator><creator>Tsitsopoulos, Eustathios</creator><creator>Moshoyianni, Hariklia</creator><creator>Manolakopoulos, Spilios</creator><creator>Pektasides, Dimitrios</creator><creator>Thanopoulou, Anastasia</creator><general>American Diabetes Association</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M2O</scope><scope>M2P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PADUT</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-9361-9459</orcidid></search><sort><creationdate>20220101</creationdate><title>Noninvasive, Blood-Based Biomarkers as Screening Tools for Hepatic Fibrosis in People With Type 2 Diabetes</title><author>Meritsi, Angeliki ; Latsou, Dimitra ; Manesis, Emanuel ; Gatos, Ilias ; Theotokas, Ioannis ; Zoumpoulis, Pavlos ; Rapti, Stamatia ; Tsitsopoulos, Eustathios ; Moshoyianni, Hariklia ; Manolakopoulos, Spilios ; Pektasides, Dimitrios ; Thanopoulou, Anastasia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3184-fdc24528191f8419f5e2bb608898087e87ac0ec61a56554ba84f97ebdb312d3f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Biomarkers</topic><topic>Diabetes</topic><topic>Liver diseases</topic><topic>Medical screening</topic><topic>Pandemics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Meritsi, Angeliki</creatorcontrib><creatorcontrib>Latsou, Dimitra</creatorcontrib><creatorcontrib>Manesis, Emanuel</creatorcontrib><creatorcontrib>Gatos, Ilias</creatorcontrib><creatorcontrib>Theotokas, Ioannis</creatorcontrib><creatorcontrib>Zoumpoulis, Pavlos</creatorcontrib><creatorcontrib>Rapti, Stamatia</creatorcontrib><creatorcontrib>Tsitsopoulos, Eustathios</creatorcontrib><creatorcontrib>Moshoyianni, Hariklia</creatorcontrib><creatorcontrib>Manolakopoulos, Spilios</creatorcontrib><creatorcontrib>Pektasides, Dimitrios</creatorcontrib><creatorcontrib>Thanopoulou, Anastasia</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Research Library China</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical diabetes</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Meritsi, Angeliki</au><au>Latsou, Dimitra</au><au>Manesis, Emanuel</au><au>Gatos, Ilias</au><au>Theotokas, Ioannis</au><au>Zoumpoulis, Pavlos</au><au>Rapti, Stamatia</au><au>Tsitsopoulos, Eustathios</au><au>Moshoyianni, Hariklia</au><au>Manolakopoulos, Spilios</au><au>Pektasides, Dimitrios</au><au>Thanopoulou, Anastasia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Noninvasive, Blood-Based Biomarkers as Screening Tools for Hepatic Fibrosis in People With Type 2 Diabetes</atitle><jtitle>Clinical diabetes</jtitle><addtitle>Clin Diabetes</addtitle><date>2022-01-01</date><risdate>2022</risdate><volume>40</volume><issue>3</issue><spage>327</spage><epage>338</epage><pages>327-338</pages><issn>0891-8929</issn><eissn>1945-4953</eissn><abstract>Nonalcoholic fatty liver disease (NAFLD) is dramatically increasing in parallel with the pandemic of type 2 diabetes. Here, the authors aimed to assess the performance of the most commonly used noninvasive, blood-based biomarkers for liver fibrosis (FibroTest, NAFLD fibrosis score, BARD score, and FIB-4 Index) in subjects with type 2 diabetes. Liver stiffness measurement was estimated by two-dimensional shear wave elastography. Finally, the authors assessed the diagnostic role of ActiTest and NashTest 2 in liver fibrosis in the examined population.</abstract><cop>United States</cop><pub>American Diabetes Association</pub><pmid>35983425</pmid><doi>10.2337/cd21-0104</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0001-9361-9459</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0891-8929
ispartof Clinical diabetes, 2022-01, Vol.40 (3), p.327-338
issn 0891-8929
1945-4953
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9331611
source PMC (PubMed Central); Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Biomarkers
Diabetes
Liver diseases
Medical screening
Pandemics
title Noninvasive, Blood-Based Biomarkers as Screening Tools for Hepatic Fibrosis in People With Type 2 Diabetes
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T00%3A04%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Noninvasive,%20Blood-Based%20Biomarkers%20as%20Screening%20Tools%20for%20Hepatic%20Fibrosis%20in%20People%20With%20Type%202%20Diabetes&rft.jtitle=Clinical%20diabetes&rft.au=Meritsi,%20Angeliki&rft.date=2022-01-01&rft.volume=40&rft.issue=3&rft.spage=327&rft.epage=338&rft.pages=327-338&rft.issn=0891-8929&rft.eissn=1945-4953&rft_id=info:doi/10.2337/cd21-0104&rft_dat=%3Cproquest_pubme%3E2704871839%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2691095069&rft_id=info:pmid/35983425&rfr_iscdi=true